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Introduction	  	   Liver	   cirrhosis	   is	   a	   debated	   problem	   in	   hepatology.	   Pathologists	   define	   it	   as	   the	  presence	  of	  a	  high	  transformation	  of	   liver	   tissue,	  where	   inflammatory	  disease	  of	  peri-­‐portal	  space,	  new	  nodule	  of	  hepatic	  regenerative	  tissue	  and	  bridging	  fibrosis	  through	  portal	  spaces	  coexist.	   METAVIR	   or	   Ishak	   pathological	   scores,	   describe	   cirrhosis	   as	   the	   worst	   damage	   in	  chronic	   liver	   disease,	   which	   corresponds	   to	   the	   highest	   amount	   of	   fibrosis	   apposition.	  Cirrhosis	   is	   also	   characterised	   by	   clinical	   features,	   much	   of	   them	   related	   to	   portal	  hypertension	   and	   loss	   of	   liver	   function.	   Seldom	   clinical	   and	   histological	   cirrhosis	   are	  synchronous	  and	   the	   latter	   is	  not	   always	   followed	  by	   the	  development	  of	   complications1.	  A	  status	   of	   compensated	   cirrhosis	   could	   last	   years	   before	   the	   comparison	   of	   complications.	  Nonetheless,	  people	  with	  well-­‐compensated	  cirrhosis	  have	  longer	  life	  expectancies	  and	  a	  low	  mortality	  rate,	  compared	  to	  decompensating	  patients2.	  Main	  complications,	  such	  oesophageal	  varices	  and	  ascites,	  are	  principally	  connected	  to	  portal	  hypertension.	  Bridging	  fibrosis	  around	  portal	   spaces,	   a	   growing	   presence	   of	   regenerative	   nodules	   and	   the	   progressive	   epithelia	  deposition	  in	  sinusoids	  increase	  pressure	  in	  portal	  venous	  system,	  leading	  to	  development	  of	  both	  ascites	  and	  porto-­‐systemic	  shunts	  as	  oesophageal	  varices.	  Portal	  pressure	  increase	  could	  also	   carry	   to	   oesophageal	   bleeding,	   the	   worst	   and	   life-­‐threatening	   emergency	   in	   cirrhosis.	  Nonetheless,	   portal	   hypertension	   generates	   a	   decrease	   of	   splanchnic	   circulation	   resistance	  and	   a	   redistribution	   of	   blood	   during	   a	   later	   phase,	   bringing	   hepatic-­‐renal	   syndrome	   and	  chronic	  ascites,	   refractory	   to	  diuretic	   treatments.	  Thus,	   there	   is	  a	  pressing	  need	   to	   redefine	  cirrhosis,	   in	  a	  manner	  that	  better	  describes	  patients	  with	  chronic	   liver	  disease,	  pointing	  out	  favourable	  and	  unfavourable	  endpoints	   that	  correlates	  with	  distinct	  clinical	  outcome3.	  After	  Baveno	   Consensus	   Conference	   in	   2005,	   a	   classification	   has	   been	   purposed	   that	   stratifies	  population	   in	   four	   clinical	   classes	   of	   growing	   severity	   in	   order	   to	   plan	   an	   adequate	   clinical	  
management.	   The	   classification	   discerns	   between	   stage	   1	   and	   2	   of	   patients	  without	   ascites	  and	   varices,	   or	   patients	   with	   only	   varices,	   that	   have	   a	   similar	   life	   expectancies	   (1-­‐3,4%	   of	  mortality	  risk	  per	  year)	  and	  risk	  of	  decompensation.	  The	  third	  stage	  comprises	  patients	  who	  developed	  both	  varices	  and	  ascites.	  The	  risk	  of	  bleeding	  is	  higher	  than	  stage	  1	  or	  2,	  so	  patients	  should	  be	  strictly	  followed	  with	  endoscopy	  at	  least	  every	  year	  and	  treated	  with	  non-­‐selective	  beta-­‐blockers	  (mortality	  risk	  at	  1	  year	  20%).	  Finally,	  stage	  4	  comprises	  patient	  with	  variceal	  bleeding,	  a	  life	  threatening	  adverse	  event	  with	  a	  mortality	  risk	  of	  57%	  per	  year2,	  4.	  	  Portal	   pressure	   assessment	   has	   always	   been	   considered	   a	   useful	   tool	   in	   clinical	  management.	   Originally,	   it	  was	   accomplished	   by	   the	   direct	   puncture	   of	   the	   portal	   trunk	   or	  intrahepatic	   or	   intra-­‐splenic	   portal	   branches,	   but	  was	   dangerous	   and	   full	   of	   adverse	   event.	  Almost	  50	  years	  ago,	  Wegde	  Hepatic	  Venous	  Pressure	  (WHVP)	  measurement	  showed	  a	  safer	  profile	  and	  substituted	  direct	  portal	  puncture5.	  Cannulating	  the	  jugular	  vein	  or	  brachial	  vein	  and	  approaching	  the	  hepatic	  vein	  is	  possible	  to	  measure	  WHVP	  by	  blocking	  the	  catheter	  with	  a	   balloon.	   After	   that,	   Free	   Hepatic	   Venous	   Pressure	   (FHVP)	   could	   be	   sampled,	   leaving	   the	  catheter	  flowing	  free	  in	  hepatic	  vein	  flow.	  The	  difference	  between	  WHVP	  and	  FHVP,	  give	  the	  Hepatic	  Venous	  Pressure	  Gradient	  (HVPG)	  that	  is	  directly	  related	  to	  portal	  pressure.	  HVPG	  is	  today	   the	   gold	   standard	   in	   portal	   hypertension	   assessment	   and	   it	   could	   stratify	   cirrhotic	  patients	  according	  to	  risk	  of	  decompensation	  and	  death2.	  Indeed,	  a	  pressure	  gradient	  higher	  than	  5	  mmHg	  identifies	  the	  presence	  of	  Portal	  Hypertension	  (PH)	  whereas	  a	  gradient	  above	  or	   equal	   to	   10	   mmHg	   is	   associated	   to	   a	   status	   of	   Clinical	   Significant	   Portal	   Hypertension	  (CSPH)	   6.	   CSPH	   is	   related	   to	   a	   bad	  prognosis,	   also	   in	   patient	  without	   esophageal	   varices	   or	  ascites,	  and	  is	  a	  sign	  of	  cirrhosis	  evolution.	  Once	  the	  presence	  of	  CSPH	  has	  been	  demonstrated,	  patients	   should	  undergo	   to	  a	   strict	   follow	  up	  with	  esophagel-­‐gastro-­‐endoscopy	  once	  a	  year.	  The	   16	   mmHg	   threshold	   defines	   a	   status	   of	   Severe	   Portal	   Hypertension	   correlating	   with	  severe	  risk	  of	  death7.	  Nonetheless,	  HVPG	  is	  the	  best	   independent	  marker	  of	  outcome	  during	  
variceal	  bleeding.	  Patients	  with	  a	  decrease	  of	  HVPG	  after	  beta-­‐blocker	  therapy,	  have	  a	  better	  clinical	   outcome8,	   9.	   Even	   useful,	   HVPG	   measurement	   is	   minimally	   invasive,	   creating	  discomfort	  to	  the	  patient,	  and	  expensive,	  increasing	  the	  cost	  of	  medical	  care	  and	  the	  amount	  of	   medical	   providers.	   Nonetheless,	   these	   limits	   avoid	   the	   possibility	   to	   repeat	   HVPG	   and	  follow	  the	  development	  of	  portal	  hypertension	   in	  single	  patients.	  Thus,	  scientific	  strains	  are	  turned	   to	   the	   identification	  of	   non-­‐invasive,	   cost-­‐effective	   and	   easy-­‐repeatable	   technique	   to	  predict	  the	  presence	  of	  severe	  portal	  hypertension10.	  Despite	  new	  technological	  development,	  nothing	  has	  been	  found	  that	  suits	  perfectly,	  even	  if	  new	  device	  are	  now	  under	  evaluation.	  The	  characteristics	  of	  US	  evaluation	  make	  it	  useful	  in	  portal	  hypertension	  assessment.	  Guidelines	  suggest	  that	  every	  patient	  with	  cirrhosis	  should	  undergo	  at	  least	  one	  US	  scan	  every	  six	  months	  and	  US	  scan	  should	  be	  the	  first	  line	  assessment	  in	  suspect	  of	  portal	  hypertension11.	  Doppler	  and	  B-­‐Mode	  US	  signs	  showed	  a	  high	  specificity	   for	  CSPH	  and	  are	  slightly	  related	  to	  HVPG12	  (Berzigotti	   J	  Gastroenterology	  2011).	  Nonetheless,	  their	  concomitant	  presence	  has	  a	  good	   positive	   prognostic	   value11.	   Spleen	   enlargement	   and	   dilatation	   of	   portal	   trunk	   or	   its	  confluents	   are	   the	   main	   grey	   scale	   US	   signs	   of	   portal	   hypertension.	   Even	   more,	   the	  identification	   of	   porto-­‐systemic	   collaterals	   strongly	   correlates	   with	   HVPG	   higher	   than	   16	  mmHg,	   identifying	   patients	  with	   a	   bad	  prognosis12.	   Ultrasound	   is	   also	   sensible	   in	   detecting	  subclinical	  ascites	  especially	  in	  perihepatic	  spaces.	  Doppler	  is	  almost	  useful	  in	  the	  assessment	  of	  portal	  blood	   flow.	  Presence	  of	  hepatofugal	  portal	   flux	  and	   flux	  velocity	  below	  24	  cm/s	   in	  portal	  trunk	  are	  highly	  specific	  for	  the	  presence	  of	  CSPH13.	  Other	  parameters	  as	  the	  flattening	  of	  hepatic	  vein	  flow	  and	  the	  increase	  of	  splenic	  and	  hepatic	  artery	  resistance	  indexes	  (RI)	  are	  still	  under	  debate.	  Contrarily,	  the	  decrease	  of	  resistance	  index	  in	  superior	  mesenteric	  artery14	  and	  the	  increase	  of	  RI	  of	  renal	  cortex	  arteries15	  are	  signs	  of	  the	  splancnic	  redirection	  of	  blood	  and	   renal	   reaction,	   maybe	   bringing	   to	   the	   development	   of	   hepatic-­‐renal	   syndrome.	  Unfortunately,	  the	  majority	  of	  scientific	  studies	  on	  this	  field	  are	  mainly	  case	  control	  studies	  or	  
case	   series	   of	   patients,	   producing	   only	   weak	   evidences.	   Control	   randomized	   trials	   are	  lacking11.	   Worth	   noting	   is	   also	   the	   choice	   of	   patients	   population,	   where	   the	   diagnosis	   of	  clinical	   significant	   portal	   hypertension	   has	   been	   assessed	   by	   the	   meanwhile	   presence	   of	  varices,	   splenomegaly	   and	   platelets	   count	   less	   than	   100000/mmc,	   instead	   of	   an	   HVPG	  measurement	   higher	   than	   9	   mmHg16.	   Moreover,	   US	   technique	   is	   also	   strongly	   operator-­‐dependant.	   Especially	   Doppler	   assessment	   suffers	   of	   a	   huge	   inter-­‐observer	   and	   inter-­‐equipment	  variability17.	  Recently	   new	   machines	   have	   been	   developed	   to	   assess	   tissue	   stiffness,	   basing	   on	  generation	  of	  shear	  wave	  and	  Ultrasound	  physic.	  First	  and	  foremost,	  Transient	  Elastography	  (Fibroscan)	   was	   purpose	   by	   Echosens	   to	   assess	   liver	   stiffness	   in	   patients	   with	   chronic	  hepatitis,	  riding	  the	  need	  to	  estimate	  liver	  fibrosis	  degree	  in	  a	  non-­‐invasive	  way18.	  Fibroscan	  probe	  contains	  both	  a	  low	  frequency	  vibrator	  (50	  Hz)	  and	  an	  ultrasonic	  3,5-­‐5	  MHz	  transducer.	  The	   operator	   usually	   places	   the	   probe	   in	   the	   right	   intercostal	   spaces	   (Figure	   1)18.	   The	  vibrator	  generates	  a	  low-­‐amplitude	  mechanic	  wave	  propagating	  to	  liver	  tissue.	  US	  transducer	  follow	  elastic	  wave	  and	  allows	  the	  measurement	  of	  its	  velocity	  inside	  a	  4	  x	  1	  cm	  ROI	  located	  at	  2,5	  cm	  under	  the	  skin	  surface.	  The	  transducer	  could	  also	  produce	  an	  M-­‐Mode	  image	  (1	  to	  6	  cm	  from	   skin	   surface)	   that	   help	   the	   operator	   to	   guide	   the	  measurement	   avoiding	   fibrotic	   and	  vascular	  structure	  inside	  the	  liver	  parenchyma.	  Final	  stiffness	  result	  is	  the	  median	  value	  of	  ten	  valid	  measurements;	  it	  is	  expressed	  in	  Kilopascal	  units	  (kPa)	  with	  a	  maximum	  allowed	  IQR	  of	  30%	   and	   a	   Success	   Rate	   of	   60%.	   Transient	   Elastography	   showed	   some	   good	   results	   in	  assessment	  of	  chronic	  liver	  disease.	  Although	  it	  could	  not	  substitute	  biopsy	  at	  all,	  the	  13.0	  kPa	  threshold	   has	   been	   demonstrated	   to	   identify	   patients	   with	   or	   without	   cirrhosis	   with	   an	  excellent	   accuracy	   and	   independently	   from	   the	   hepatic	   disease19.	   However,	   the	   technique	  showed	   only	  weak	   results	   in	   diagnosis	   of	   clinical	   significant	   fibrosis	  with	   high	   variation	   of	  AUROC,	   according	   to	   liver	   disease	   aetiology19.	   Nonetheless,	   Fibroscan	   shows	   also	   other	  
advantages.	  It	   is	  easily	  repeatable,	  free	  from	  dangerous	  side	  effects	  and,	  differently	  from	  US,	  reasonably	   operator	   independent.	   Therefore,	   it	   could	   be	   performed	   frequently	   to	   monitor	  fibrosis	  progression20.	  Despite	  a	  good	  correlation	  with	   liver	  fibrosis,	  other	   liver	  pathological	  feathers	  could	   influence	   liver	   stiffness.	  Thus,	  Fibroscan	  has	  also	  been	  purpose	   to	  assess	   the	  presence	   of	   portal	   hypertension	   and	   to	   predict	   the	   presence	   of	   CSPH.	   Firstly,	   Fibroscan	  demonstrates	   to	   be	   accurate	   in	   predicting	   risk	   of	   developing	   cirrhosis,	   clinical	  decompensation	  and	  graft	  lost	  in	  a	  subpopulation	  liver	  transplanted	  patients	  who	  underwent	  to	  HCV	  re-­‐infection21.	  Seemly,	  in	  patients	  with	  chronic	  HCV	  infection,	  a	  correlation	  was	  found	  between	  HVPG	  measurement	  and	  liver	  stiffness.	  Regrettably,	  the	  correlation	  was	  optimal	  for	  HVPG	  less	  than	  10	  mmHg	  or	  12	  mmHg,	  but	   for	  higher	  value	  of	  HVPG	  the	  correlation	  hardly	  reach	   a	   statistical	   significance22.	   The	   authors	   argued	   that	   the	   development	   of	   a	   portal	  hypertension	  is	  only	  partially	  independent	  from	  the	  fibrotic	  transformation	  of	  the	  liver.	  After	  certain	   level	   of	   portal	   hypertension,	   some	   other	   factors,	   such	   as	   hyperdinamic	   circulation,	  collaterals	   development	   and	   splancnic	   vasodilatation	   contributes	   to	   the	   development	   of	  decompensation,	  but	  have	  no	   influence	  on	   liver	  stiffness22.	  Authors	  purpose	  13,6	  kPa	  as	  the	  best	  cut-­‐off	  to	  predict	  CSPH	  (AUROC	  0,99;	  sensitivity	  97%	  and	  specificity	  92%)	  that	  is	  never	  been	  reproduced	  in	  subsequent	  scientific	  paper	  both	  in	  HCV	  population	  (20.5	  kPa	  in	  Lemoine	  paper)	   23	   and	   in	   mixed	   population	   affected	   by	   heterogeneous	   liver	   diseases	   (21.1	   kPa	   in	  Bureau	   paper)	   24.	   Lastly,	   LS	   was	   proven	   to	   be	   independently	   associated	   with	   Portal	  Hypertension	  complications.	  No	  patients	  with	  chronic	  hepatitis	  run	  to	  decompensation	  when	  LS	   was	   less	   than	   21.1	   kPa	   both	   in	   cirrhotic	   subgroup	   and	   in	   patients	   without	   cirrhosis25.	  Despite	  good	  premises,	  Fibroscan	  has	  some	  technical	  limitation.	  US	  Operator	  could	  not	  move	  the	  ROI	  deeper	  than	  2,5	  cm	  from	  skin	  surface.	  This	  avoids	  measurements	   in	  patients	  where	  liver	  is	  deeper	  as	  obese	  patients26	  or	  in	  presence	  of	  ascites.	  Nonetheless,	  the	  transducer	  could	  not	   generate	   a	   bi-­‐dimensional	   image	   so	   the	   operator	   couldn’t	   recognise	   at	   all	   the	   structure	  
that	   are	   insonated.	   Failure	   or	   unreliable	   results	   occur	   in	   10-­‐20%	   of	   patients	   due	   to	  overweight,	  narrow	  intercostal	  spaces3,	  or	  high	  variability	  of	  measurements27.	  Moreover,	  the	  technical	   feature	   of	   the	   standard	  probe	   avoids	   stiffness	   sampling	   in	   other	   organ	   than	   liver.	  New	  probe	  were	  born	  recently,	  permitting	  the	  measurements	  on	  spleen	  or	  in	  obese	  or	  child	  patients,	  but	  are	  expensive	  and	  suffer	  of	  the	  same	  technical	  drawbacks	  of	  the	  standard	  probe.	  	  









	  	   More	   recently,	   new	   elastometric	   tools	   have	   been	   developed,	   which	   employ	   shear	  waves	  to	  assess	  liver	  stiffness.	  Embedded	  on	  common	  US	  machine,	  they	  can	  generate	  both	  an	  ultrasound	   image	   and	   stiffness	   measurement.	   Siemens	   has	   patented	   Virtual	   Touch	   Tissue	  Quantification	  Imaging	  (Siemens	  Medical	  Solution,	  Mountain	  View,	  CA,	  USA).	  Virtual	  Touch™	  allows	   the	   operator	   to	   place	   a	   small	   ROI	   (0,6	   cm	   width	   and	   1	   cm	   length)	   under	   B-­‐mode	  guidance	  at	  a	  desired	  depth,	  up	  to	  8	  cm	  from	  skin	  surface.	  The	  US	  convex	  probe	  (2,5-­‐4,5	  MHz)	  
sends	  a	  high-­‐energy	  ultrasound	  pulses	  at	  a	  fixed	  transmit	  frequency	  of	  2,67	  MHz.	  It	  produces	  a	  mechanical	  excitation	  along	   the	  wave	  propagation	  path,	  generating	  a	  double	  shear	  waves,	  called	   Acoustic	   Radiation	   Force	   Impulses	   (ARFI),	   that	   are	   opposite	   phased,	   parallel	   and	  laterally	  sided	  to	  the	  ROI.	  The	  US	  machine	  calculates	  the	  shear	  wave	  speed	  by	  measuring	  the	  time	   to	   peak	   displacement	   at	   each	   lateral	   location	   until	   the	   ROI	   depth.	   Displacement	  magnitude	   is	   connected	   to	   the	   local	   tissue	   stiffness	   and	   its	   velocity	   is	   connected	   to	   the	  viscoelastic	  proprieties	  of	  tissue28.	  Thus,	  stiffness	  is	  expressed	  in	  m/s	  (range	  0,5-­‐4,4	  m/s	  with	  a	  ±	  20%	  accuracy).	  While	  number	  of	  measurements	  and	  success	  rate	  are	  clearly	  defined	  by	  Echosense	  for	  Transient	  Elastography,	  ARFI	  measurement	  has	  not	  been	  already	  standardized.	  Similarly	   to	   Fibroscan,	   Virtual	   Touch™	   shows	   a	   good	   performance	   in	   prediction	   of	   fibrosis.	  Recently,	   a	   meta-­‐analysis	   has	   summarized	   the	   data	   from	   eight	   different	   studies	   published	  between	  2009	  and	  2011.	   It	  collects	  about	  518	  patients	  with	  chronic	  hepatitis,	  analysing	  the	  performance	  of	  Virtual	  Touch™	  in	  assessing	  the	  degree	  of	  fibrosis.	  The	  diagnostic	  accuracy	  of	  ARFI	   quantified	   by	  AUROC	  was	  87%	   in	   significant	   fibrosis	   (liver	   stiffness	   cut-­‐off	   1,34	  m/s)	  growing	  up	  to	  91%	  and	  93%	  in	  severe	  fibrosis	  and	  cirrhosis	  (cut-­‐off	  1,55	  m/s	  and	  1,80	  m/s)	  
29.	   Slightly	   but	   significant	   higher	   accuracy	  was	   found	   comparing	   Transient	   Elastography	   to	  ARFI	   in	   predicting	   significant	   fibrosis	   and	   cirrhosis.	   The	   authors	   ascribe	   the	   worst	  performances	   of	   ARFI	   to	   the	   little	   accordance	   of	   sampling	  methods	   and	   sites	   between	   the	  papers	  of	  meta-­‐analysis29.	  The	  diagnostic	  power	  to	  discern	  between	  fibrosis	  stages	  increases	  according	  to	  the	  severity	  of	   fibrosis	  with	  both	  Virtual	  Touch™	  and	  Fibroscan30.	  According	  to	  Ebinuma	   and	   Friedrich-­‐Rust	   the	   techniques	   showed	   higher	   diagnostic	   power	   when	   liver	  fibrosis	   is	  more	   severe29,	  30.	   Although	   Virtual	   Touch™	   is	   little	   less	   accurate	   than	   Fibroscan,	  advantages	   are	   evident.	   The	   usefulness	   of	   the	   integration	   between	   B-­‐mode	   imaging	   and	  stiffness	   measurement	   allows	   changing	   the	   sampling	   depth,	   avoiding	   the	   need	   of	   several	  probes.	   Nevertheless,	   also	   patients	   with	   ascites	   might	   be	   evaluated.	   Consequently,	   overall	  
failure	  rate	  has	  been	  reported	  to	  be	  2,9%,	  impressively	  less	  than	  Fibroscan29.	  Even	  more,	  the	  flexibility	   of	   ROI	   placement	   shows	   its	   usefulness	   also	   in	   a	   setting	   of	   inhomogeneous	   liver	  fibrosis	   deposition31.	   The	   combination	   of	   US	   imaging	   and	   stiffness	  measurement	   of	   Virtual	  Touch™	   allows	   also	   the	   assessment	   of	   other	   organ	   than	   liver.	   Spleen	   stiffness	   accurately	  identifies	  patients	  with	  cirrhosis	   (87,1%	  accuracy	  with	  2,51	  m/s	  spleen	  stiffness	  cut	  off)	   32.	  Contrarily,	   liver	   stiffness	   and	   spleen	   stiffness	   did	   not	   show	   a	   sure	   correlation	   with	   the	  presence	   of	   oesophageal	   varices	   at	   EGDS	   and	   could	   not	   predict	   the	   degree	   of	   varices	   in	  cirrhotic	  population32,	  33.	  	  
Aims	  	   The	   location	  of	   spleen,	   upstream	   to	   the	  portal	   system,	  makes	   it	   interesting	   to	   assess	  stiffness	  in	  portal	  hypertension.	  Albeit,	  no	  studies	  are	  now	  available	  on	  portal	  hypertension,	  where	  stiffness	  measured	  with	  Virtual	  Touch™	  is	  matched	  to	  HVPG.	  Thus,	  aim	  of	  the	  study	  is	  to	  assess	  a	  potential	  relationship	  between	  spleen	  and/or	  liver	  stiffness,	  with	  Hepatic	  Venous	  Pressure	  Gradient,	   in	   order	   to	   find	   if	  ARFI	   values	   could	  be	   considered	   surrogate	  marker	   of	  portal	  hypertension.	  	  	  
Methods	  	   During	   July	   and	   September	   2011,	   all	   consecutive	   patients	   who	   underwent	   to	   HVPG	  measurement,	   were	   prospectively	   considered	   for	   the	   inclusion	   in	   the	   study	   protocol.	   All	  patients	   without	   hepatic	   chronic	   disease	   and	   with	   portal	   thrombosis,	   previous	   spleen	  resection,	  transaminases	  level	  up	  to	  10	  times	  the	  normal	  level	  or	  advanced/intermediate	  HCC	  were	  excluded.	  We	  admitted	  patients	  with	  early	  HCC	  inside	  Milan	  criteria.	  	  
ARFI	  was	  performed	  at	  least	  one	  week	  before	  HVPG.	  Sonographer	  (A.B.)	  was	  blinded	  to	  HVPG	  report.	   Before	   examination,	   clinical	   history	   and	   blood	   examination	   were	   obtained.	  Transaminases	   level,	   gamma-­‐glutamiltranspeptidase,	   alkaline	   phosphatase,	   albumin,	  coagulation,	   total	   bilirubin	   levels	   and	   platelets	   count	   were	   collected.	   Available	   reports	   of	  oesophageal-­‐gastric	   endoscopy	  performed	  within	  2	  months	   to	  HVPG	  assessment,	  were	   also	  collected.	  The	  Etic	  Committee	  of	  S.	  Orsola	  -­‐	  Malpighi	  University	  Hospital	  of	  Bologna	  approved	  the	  study	  protocol.	  All	  patients	  gave	  their	  written	  informed	  consent	  before	  stiffness	  measurement	  and	  clinical	  data	  collection,	  in	  accordance	  with	  the	  principle	  of	  Declaration	  of	  Helsinki.	  	  
US	  imaging	  
	  The	  same	  operator	  (A.B.)	  performed	  both	  US	  scan	  and	  stiffness	  assessments	  on	  fasting	  patients.	  The	  examined	  patient	  lied	  in	  the	  dorsal	  decubitus	  position,	  with	  right	  and	  left	  arms	  bended	  behind	  the	  head.	  Before	  ARFI	  assessment,	  a	  B-­‐mode	  standard	  ultrasonography	  scan	  was	  performed	  using	  a	  Siemens	  Acuson	  S2000	  (Siemens	  Medical	  Solution,	  Mountain	  View,	  CA,	  USA)	  with	  a	  4Cl	  transducer.	  The	  operator	  checked	  the	  presence	  of	  ascites,	  liver	  steatosis	  and	  portal	  venous	  shunts12.	  Portal	  trunk	  calibre34,	  35	  and	  spleen	  size	  (both	  section	  area	  and	  bipolar	  diameter)	   were	   also	   measured36.	   Pulsatile	   Index	   (PI)	   and	   Resistance	   Index	   (RI)	   of	   intra-­‐splenic	   arteries	   (3	   samples	   for	   each	   patient	   in	   upper,	  medium	   and	   lower	   spleen)	   37,	   portal	  trunk	  flux38	  and	  hepatic	  veins	  phasic	  flux39	  were	  checked	  by	  Doppler	  analysis.	  
	  
ARFI	  measurement	  	   After	   US	   scan,	   operator	   measured	   stiffness	   using	   the	   same	   probe	   of	   abdominal	  exploration	   (4Cl).	   Sonographer	   asked	   to	   the	   patient	   to	   hold	   on	   the	   breath	   during	   every	  stiffness	  sampling.	  Stiffness	  was	  measured	  choosing	  two	  areas	  in	  the	  right	  liver	  lobe,	  an	  area	  in	  the	  left	  lobe	  and	  two	  areas	  in	  the	  spleen,	  avoiding	  vessels	  or	  fibrotic	  structures	  that	  could	  affect	   the	   results.	   In	   the	   right	   lobe,	   stiffness	   was	   sampled	   in	   5th	   or	   6th	   segment	   through	  intercostal	  spaces,	  both	  at	  1	  cm	  (Right	  Lobe	  Surface)	  and	  5	  cm	  (Right	  Lobe	  Centre)	  from	  liver	  surface.	  In	  the	  left	  lobe,	  stiffness	  was	  assessed	  between	  2nd	  and	  3rd	  segment	  portal	  branches	  (Left	  Liver)	  placing	  the	  US	  probe	  on	  a	  longitudinal	  axis.	  Spleen	  stiffness	  was	  assessed	  both	  at	  superior	  (Superior	  Spleen)	  and	  inferior	  half	  spleen	  region	  (Inferior	  Spleen).	   Just	  by	  pointing	  ROI	  and	  clicking,	  US	  machine	  could	  measure	  stiffness	  expressing	  results	  in	  meters	  per	  second	  (m/s)	  as	  showed	  in	  Figure	  2.	  Sonographer	  should	  perform	  at	  least	  10	  successful	  measures	  in	  every	  sample	  areas,	  with	  a	  60%	  Success	  Rate	  (SR).	  




HVPG	  	  WHVP,	   FHVP	   and	   HVPG	   measurements	   were	   performed	   in	   the	   Angiography	   Room	  (Radiologia	  Dr.ssa	  Rita	  Golfieri)	  according	  to	  standard	  protocol	  of	  S.Orsola-­‐Malpighi	  Hospital.	  A	   7	   French	   catheter	   was	   placed	   in	   the	   basilica	   vein	   of	   the	   right	   forearm,	   using	   Seldinger	  technique.	   A	   5	   French	   balloon-­‐tipped	   catheter	   (OB-­‐Medi_Tech,	   Boston	   Scientific	   Cork	   Ltd.,	  Cork,	  Ireland)	  was	  advanced	  into	  the	  right	  hepatic	  vein	  to	  measure	  WHVP	  and	  FHVP.	  Balloon	  catheter	   was	   inflating	   to	   obtain	   the	   wedge	   position.	   The	   injection	   of	   a	   small	   amount	   of	  medium	   confirmed	   the	   occlusion	   of	   hepatic	   vein.	   An	   external	   electromechanical	   transducer	  and	   polygraph	   connected	   to	   OB	   catheter	   (PowerLab,	   ADI	   Instruments,	   Milford,	   MA,	   USA)	  recorded	  FHVP	  for	  at	  least	  20	  seconds	  and	  WHVP	  for	  at	  least	  40	  seconds	  until	  the	  stability	  of	  measurements.	  The	  procedures	  were	  performed	  by	  experienced	  radiologists	  (C.M.	  and	  M.R.),	  and	  were	   supervised	  by	  a	  hepatologist	   (P.Z.	  or	  C.T.)	   for	   the	   recording	  and	   interpretation	  of	  pressure	  tracing.	  HVPG	  was	  calculated	  as	  the	  difference	  between	  WHVP	  and	  FHVP.	  Permanent	  tracing	  were	  recorded,	  according	  to	  the	  published	  guidelines40.	  	  
Statistic	  analysis	  	  
	  Median	  values,	  SR	  and	  IQR	  of	  all	  measurements	  in	  each	  patient	  were	  calculated.	  1) Scatter-­‐plot	   distribution	   of	   ARFI	   (median	   vs.	   interquartile	   range)	   was	   provided	   to	  compare	  the	  difference	  between	  quantiles	  and	  interquartiles	  both	  in	  liver	  and	  spleen.	  2) Correlations	  between	  stiffness	  and	  HVPG	  were	  accomplished	  with	  Spearman	  bivariate	  analysis	  until	  our	  data	  were	  not	  normally	  distributed.	  AUROC	  analysis	  was	  performed	  to	  assess	   the	   accuracy	   of	   ARFI	   in	   predicting	   a	   HVPG	   higher	   than	   10,12	   or	   16	   mmHg.	  
According	   to	   AUROC,	   optimal	   cut-­‐off	   was	   chosen	   according	   to	   the	   maximal	   sum	   of	  sensitivity	  and	  specificity.	  Graphic	  box-­‐plots	  were	  also	  provided	  to	  assess	  the	  power	  of	  ARFI	  values	  to	  discern	  group	  of	  patients	  with	  HVPG≥10,	  12	  and	  16	  mmHg	  and	  patients	  with	  or	  without	  varices.	  	  3) Confounding	   factors	   analysis	   was	   performed	   using	   univariate	   and	   multivariate	  regression	  analysis	  to	  evaluate	  weather	  their	  presence	  or	  elevation	  could	  influence	  the	  outcome	  of	  Virtual	  Touch™.	  Data	   were	   collected	   in	   Excel	   file	   (Mac	   version	   2011;	   Microsoft	   Corporation,	   Redmond,	  Washington)	  and	  statistical	  analysis	  was	  performed	  by	  using	  the	  SPSS	  statistical	  package	  for	  Machintosh	  (SPSS	  16.0,	  SPSS	  Inc.	  IBM,	  Chicago,	  IL,	  USA).	  	  
Results	  	  
Population	  
	  Forty-­‐two	   consecutive	   patients	   were	   considered	   valid	   for	   the	   inclusion	   criteria.	   Two	  patients	   were	   excluded	   from	   the	   study	   after	   withdrawal	   of	   consent	   to	   catheterisation	  procedure.	  Thus,	  40	  patients	  finally	  underwent	  to	  HVPG	  measurement	  and	  were	  enrolled	  in	  the	  study.	  Patients	  characteristic	  are	   included	  in	  Table	  1.	  Thirty	  patients	  were	  male	  (75%).	  Mean	  age	  was	  62±9.9	  years.	  Mean	  BMI	  value	  was	  26±3.8	  kg/h2.	  Most	  frequent	  aetiology	  was	  HCV-­‐related	  chronic	  hepatitis	  (16	  patients).	  Six	  patients	  had	  HBV-­‐related	  chronic	  hepatitis,	  4	  alcohol-­‐related	   hepatitis	   and	   7	   cryptogenic	   hepatitis.	   Almost	   7	   patients	   had	   combining	  etiologic	   factors	   (2	   HCV/Alcohol,	   1	   HCV/Hemochromatosis	   and	   4	   HBV/HDV).	   Five	   patients	  had	   ascites,	   not	   clinically	   evident,	   whereas	   2	   patients	   had	  mild-­‐abundant	   ascites,	   clinically	  evident.	  
	  
Table	  1.	  Population	  characteristics	  are	  summarized	  in	  the	  table.	  	  
	  	  	   Liver	  Function	  and	  blood	  examination	  
	   Patients	   was	   both	   compensated	   or	   decompensated.	   Mean	   Child	   Pugh	   Score	   was	   A6	  (range	  A5-­‐B9);	  11	  patients	  have	  an	  unpaired	  liver	  function	  with	  a	  Child	  Pugh	  above	  A	  level.	  Five	  patients	  have	   little	   ascites,	   not	  detectable	   at	  physical	   examination,	   and	  2	  of	   them	  mild	  ascites.	  None	  of	  them	  showed	  Encephalopathy.	  Blood	  examination	  are	  expressed	  as	  mean±SD:	  total	  Bilirubin	  value	  was	  1,41±1,28	  mg/dl,	  Albumin	  3,71±0,62	  g/dl,	  INR	  1,27±0,3,	  GOT	  63±38	  U/l,	  GPT	  57±48	  U/l,	  gamma-­‐GT	  86±80	  U/l,	  ALP	  241±193	  U/l	  and	  Plt	  105000±53.000/mmc.	  	  
Total	  patients	  (n)	   40	  
Age	  (mean;	  years)	   62	  (range	  40-­‐80)	  
Gender	   10	  Female	  (25%)	  and	  30	  Male	  (75%)	  
Chronic	  liver	  disease	  aetiology:	  HCV	  HBV	  Alcohol	  Cryptogenic	  HCV/alcohol	  HCV/hemochromatosis	  HBV/HDV	  
	  16	  6	  4	  7	  2	  1	  4	  
BMI	   26	  (range	  20-­‐38)	  
Diabetes	   17	  
	   EGDS	  
	  	   33	  patients	  underwent	  also	   to	  EGDS	  within	  one	  month	   from	  HVPG	  measurement.	  18	  patients	  have	  varices	  at	  endoscopy.	  F1	  varices	  were	  found	  in	  13	  patients,	  F2	  in	  4	  patients	  and	  F3	   in	   only	   1	   patient.	   Two	   patients	   have	   also	   gastric	   varices	   and	   20	   patients	   suffer	   for	  congestive	  gastropathy.	  	  	   US	  Imaging	  and	  ARFI	  Measurements	  
	  	   All	  ultrasound	  features	  of	  study	  population	  are	  summarized	  in	  Table	  2.	  Steatosis	  was	  present	   at	   US	   scan	   in	   6	   patients.	   Spleen	   size	   ≥45	   cm2	   or	   diameter	   ≥	   12	   cm36,	   portal	   trunk	  diameter	  ≥	  12	  mm34,	  35,	  mean	  time	  average	  velocity	  portal	  flow	  ≤	  16	  cm/s2	  38,	  RI	  ≥	  0,66	  and	  PI	  ≥	  137	  were	  considered	  abnormal	  and	  suggestive	  of	  PH.	  Seemly,	  a	  bi/mono-­‐phasic	  hepatic	  vein	  flux39	   and	  presence	  of	  portal-­‐venous	   shunts	  were	  pathological	   findings11.	  Valid	  ARFI	   values	  were	  obtained	  in	  38	  out	  of	  40	  patients	  on	  Right	  Lobe	  Surface	  (95%	  global	  success),	  because	  the	  presence	  of	  abundant	  ascites	  avoids	  ARFI	  sampling	  in	  2	  of	  them.	  ARFI	  was	  unsuccessful	  on	  Right	  Lobe	  Centre	   in	  1	  patient	   for	  a	  44%	  SR,	  (97,5%	  global	  success	  on	  right	   lobe).	  Left	   lobe	  was	  not	  visible	  by	  ultrasound	  both	  during	  normal	  breathing	  and	  after	  deep	   inspiration	   in	  1	  patient	  and	  only	  25%	  SR	  was	  achieved	  in	  Left	  Lobe	  of	  another	  patient	  (95%	  global	  success	  on	  left	  lobe).	  Three	  inadequate	  success	  rates	  resulted	  from	  Upper	  Spleen	  stiffness	  measurement	  (92,5%	   global	   success	   on	   upper	   spleen).	   All	   ARFI	   measurements	   (Table3)	   were	   valid	   on	  Lower	  Spleen	   (100%	  global	   success	  on	   lower	  spleen).	  Mean	  ARFI	  value	  was	  2,61±0,76	  m/s	  (range	   1,2-­‐3,85	   m/s)	   on	   Right	   Lobe	   Surface,	   2,5±0,62	   m/s	   (1,11-­‐3,49	   m/s)	   on	   Right	   Lobe	  Centre,	   2,55±0,66	   m/s	   (0,82-­‐4,05	   m/s)	   on	   Left	   Lobe,	   3,17±0,55	   (2,17-­‐4,5	   m/s)	   on	   Upper	  Spleen	  and	  3,36±0,51	  m/s	  (2,3-­‐4,52	  m/s)	  on	  Lower	  Spleen.	  
Table	  2.	  Main	  US	  imaging	  features.	  In	  2	  patients	  was	  impossible	  to	  calculate	  the	  main	  portal	  calliper	  and	   in	  1	  patients	   the	  hepatic	  vein	   flux	   for	   the	  presence	  of	  abdominal	  gas	  or	   for	   the	  deepest	  position	  of	  vascular	  structures.	  Two	  patients	  had	  a	  reversed	  flux	  in	  main	  portal	  trunk.	  Seemly	  a	  patient	  has	  a	  small	  and	  hide	  spleen	  under	  diaphragm,	  so,	  spleen	  size	  could	  not	  be	  assessed.	  	  
	  
Table	  3.	  Data	  on	  stiffness	  assessment	  are	  summarized	  as	  mean	  values	  and	  standard	  deviation.	  
	  







(m/s)	  Right	  Lobe	  Surface	   38/40	   2,61±0,76	   1,2-­‐3,85	   0,51±0,3	  Right	  Lobe	  Centre	   39/40	   2,5±0,62	   1,11-­‐3,49	   0,6±0,35	  Left	  Lobe	   38/40	   2,55±0,66	   0,82-­‐4,05	   0,59±0,3	  Upper	  Spleen	   37/40	   3,17±0,55	   2,17-­‐4,5	   0,61±0,38	  Lower	  Spleen	   40/40	   3,36±0,51	   2,3-­‐4,52	   0,64±0,33	  	  
B-­‐Mode	  and	  Doppler	  
PH	  features	  
Results	  (mean)	   Un-­‐normal	  
results	  (n	  pts.)	  
No	  result	  
Steatosis	   -­‐	   6	  (15%)	   -­‐	  Portal-­‐Venous	  Shunt	   -­‐	   5	  (12,5%)	   -­‐	  Spleen	  size	  (cmq)	   74(range	  30-­‐136)	   31	  (79,5%)	   1	  Main	  Portal	  Trunk	  Calliper	  (mm)	   14(range	  9-­‐21)	   29	  (76,3%)	   2	  Spleen	  Artery	  Resistance	  Index	   0,66(range	  0,51-­‐0,93)	   19	  (47,5%)	   -­‐	  Spleen	  Artery	  Pulsatile	  Index	   1,24(range	  0,83-­‐1,72)	   33	  (82,5%)	   -­‐	  Portal	  Blood	  Flow	  Velocity	  (cm/s)	   21	  (range	  7-­‐34);	   26	  (68,4%)	   2	  Hepatic	  vein	  phasic	  flux	   -­‐	   23	  (59%)	   1	  
	  	   Data	  Analysis	  	  1) Scatterplot	  (Figure	  3)	  shows	  the	  distribution	  of	  stiffness	  median	  values	  vs.	  interquartile	  range	   (IQR)	   of	   both	   spleen	   and	   liver.	   Spleen	   stiffness	   assessments	   were	   more	  concentrated	   in	   the	   lower	   right	   part	   of	   the	   graph.	   No	   relationship	   between	   spread	   of	  values	  and	  degree	  of	   spleen	  stiffness	   could	  be	  argued.	  Differently,	  when	   liver	   stiffness	  increase	   from	  about	  1	  m/s	  (IQR	  0,4	  m/s)	   to	  3,5	  m/s	  (IQR	  1,6	  m/s),	  also	   IQR	   increase,	  showing	  how	  variability	  of	  results	  rises	  according	  to	  the	  degree	  of	  fibrosis.	  	  
Figure	   3.	   Scatterplot	   distribution	   of	   acoustic	   radiation	   force	   impulse	   (ARFI)	   values	   that	  compares	  median	  and	  IQR	  among	  spleen	  (blue	  triangles)	  and	  liver	  (red	  dots)	  samples.	  	  
	  
	  2) Bivariate	   Spearman	   non-­‐parametric	   analysis	   showed	   a	   positive	   correlation	   between	  stiffness	  values	  and	  HVPG	  but	  only	  spleen	  stiffness	  vs.	  HVPG	  correlation	  was	  statistically	  significant.	   Spearman	   r	   coefficient	  was	  0,224	   (p=	  0,176)	   for	  Right	  Lobe	  Surface,	  0,132	  (p=0,423)	   for	   Right	   Lobe	   Centre,	   0,293	   (p=0,075)	   for	   Left	   Lobe,	   0,532	   (p=0,001)	   for	  Upper	   Spleen	   and	   0,531	   (p<0,001)	   for	   Lower	   Spleen.	   Trying	   to	   reproduce	   Rizzo	  experience31,	   which	   calculated	   the	   median	   value	   of	   20	   stiffness	   measurements	   on	  several	   areas	  of	   liver,	  we	   computed	  also	   the	  median	  value	  of	   all	   20	  measurements	  on	  spleen.	   Indeed,	   since	  Virtual	  Touch™	  allows	  measuring	   stiffness	  quite	   everywhere,	  we	  thought	   that	   the	  median	   value	   of	   all	  measurements	   on	   upper	   and	   lower	   spleen	   could	  better	  mirror	  real	  spleen	  stiffness.	  37	  patients	  underwent	  to	  all	  20	  measurements;	  mean	  ±	   SD	   value	   of	   whole	   Spleen	   Stiffness	   were	   3,30±0,5	   m/s.	   Spearman	   non-­‐parametric	  analysis	  showed	  a	  higher	  correlation	  with	  HVPG	  than	  Upper	  or	  Lower	  Spleen	  stiffness	  (r=0,744;	   p<0,001).	   Figure	   4	   displays	   scatter	   plot	   of	   correlation	   between	   HVPG	   and	  spleen	  stiffness.	  
	  Figure	  4.	  Scatterplot	  shows	  the	  relationship	  between	  the	  variables	  Hepatic	  Venous	  Pressure	  Gradient	   (HVPG)	   and	   Spleen	   Stiffness,	   when	   it	   is	   calculated	   as	   the	  median	   values	   of	   all	   20	  measurements	  of	  both	  upper	  and	  lower	  side	  of	  spleen.	  	  
	  	  When	   we	   split	   population	   according	   to	   HVPG	   ≥	   10	   (Clinical	   Significant	   Portal	  Hypertension),	   12	   (High	   Risk	   of	   Complication	   Development)	   or	   16	   mmHg	   (High	  Mortality	  Risk	  Connected	  to	  Portal	  Hypertension),	  patients	  appear	  distinctly	  distributed	  in	  separate	  group	  only	  according	  to	  the	  presence	  or	  absence	  of	  CSPH	  (Figure	  5).	  Eleven	  patients	   with	   HVPG<10	   mmHg	   had	   a	   2,82	   m/s	   mean	   spleen	   stiffness;	   mean	   spleen	  stiffness	  was	  3,51	  m/s	  in	  the	  remaining	  26	  patients	  with	  HVPG≥10	  mmHg.	  Mean	  spleen	  stiffness	  was	  2,92	  m/s	  in	  14	  patients	  with	  HVPG	  <12	  had	  and	  3,54	  m/s	  in	  the	  23	  patients	  with	  HVPG≥12	  (High	  Risk	  of	  Complication	  Development).	  Twenty-­‐three	  patients	  had	  a	  HVPG<16	  mmHg	  and	  3,07	  m/s	  mean	  stiffness.	  Fourteen	  patients	  with	  HVPG≥16	  mmHg	  (High	  Mortality	  Risk	  for	  portal	  hypertension)	  had	  3,69	  m/s	  mean	  stiffness.	  	  
ROC	   analysis	   identified	   an	   ARFI	   value	   ≥	   3,26	   m/s	   as	   the	   best	   cut-­‐off	   to	   predict	   the	  presence	  of	  CSPH	  (AUROC	  0,91,	  S.E.	  0,05,	  CI	  95%	  0,82-­‐1).	  A	  3,34	  m/s	  (AUROC	  0,85,	  s.e.	  0,06,	   CI	   95%	   0,73-­‐0,97)	   is	   the	   best	   cut	   of	   to	   detect	   patients	   at	   high	   risk	   to	   develop	  complication	  connected	  to	  PH	  (HVPG≥12	  mmHg).	  Finally,	  the	  best	  Spleen	  Stiffness	  cut-­‐off	   to	  predict	  a	  High	  Mortality	  Risk	  was	  3,51	  m/s	  (AUROC	  0,86,	  s.e.	  0,06,	  CI	  95%	  0,74-­‐0,99).	   The	   concordance	   rate	   of	   ARFI	   cut-­‐offs	   and	   angiographic	   diagnosis	   of	   portal	  hypertension	  was	  calculated.	  CSPH	  cut-­‐off	   reached	  a	  concordance	  of	  75,7%	  (k=0,505).	  Concordance	  between	  ARFI	  ≥	  3,34	  m/s	  vs.	  HVPG≥12	  mmHg	  was	  70,3%	  (k=0,424),	  and	  between	  ARFI≥	  3,51	  m/s	  vs.	  HVPG	  ≥	  16	  mmHg	  concordance	  was	  81,1%	  (k=0,592).	  	  A	  box	  plot	  analysis	  was	  also	  provided	  according	  to	  the	  presence	  of	  varices	  in	  the	  set	  of	  patients	  who	  underwent	  to	  oesophageal-­‐gastric	  endoscopy	  (Figure	  6).	  The	  graph	  shows	  that	   spleen	   stiffness	   could	   not	   satisfactory	   discern	   patients	   with	   or	   without	   varices,	  because	   an	   overlap	   of	   spleen	   stiffness	   values	   was	   found	   within	   the	   two	   groups	   of	  patients.	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Figure	   5.	   The	   three	   box-­‐plots	   showed	  the	   distribution	   of	   stiffness	   values	  according	  10,	  12	  and	  16	  mmHg	  cut	  offs.	  Stiffness	  could	  discern	  groups	  of	  patients	  with	   HVPG	   higher	   or	   lower	   10	   mmHg	  (panel	   A),	   but	   when	   we	   try	   to	   split	  population	  according	  12	  mmHg	  a	  partial	  overlap	   appears	   (panel	   B).	   Seemly,	   an	  outlier	  (patient	  n°	  30)	  appears	  in	  the	  set	  of	  patients	  with	  HVPG<16	  mmHg,	  having	  4,1	  m/s	  of	  spleen	  stiffness	  and	  15	  mmHg	  of	  HVPG	  (panel	  C).	  















	  	  	  3) The	  analysis	  of	  confounding	  factors	  was	  provided	  testing	  the	  effects	  on	  spleen	  stiffness.	  Discrete	   (Child-­‐Pugh)	  and	  continuous	  (BMI,	   spleen	  dimension,	  GPT	   level)	   independent	  variables	   were	   correlated	   to	   spleen	   stiffness	   in	   linear	   regression	   univariate	   model	  showing	  no	  significant	  correlation	  between	  spleen	  stiffness	  and	  BMI	  (t=0,030,	  p=0,976)	  or	  GPT	  level	  (t=-­‐0,882,	  p=0,384).	  A	  correlation	  was	  found	  at	  univariate	  and	  multivariate	  with	   Child-­‐Pugh	   score	   (t=2,981,	   p=	   0,005)	   and	   spleen	   size	   (t=4,01,	   p<0,001	  respectively).	  	  
Figure	  6.	  Box	  plot	  shows	  the	  distribution	  of	  spleen	  stiffness	  values	  according	   to	   the	  presence	  or	  absence	  of	  varices	   in	  patients	  that	   underwent	   to	   oesophageal-­‐gastric	  endoscopy	   within	   a	   month	   from	   HVPG	  assessment.	  
	  
Discussion	  	   Actually,	  HVPG	  is	  the	  gold	  standard	  in	  portal	  pressure	  assessment,	  playing	  a	  key	  role	  in	  clarification	  of	  portal	  hypertension’s	  pathophysiology.	  It	  is	  almost	  helpful	  in	  figuring	  survival	  and	   complication	   risk,	   providing	   essential	   information	   in	   clinical	   management	   of	   patients	  with	   liver	   cirrhosis40.	   Guidelines	   strongly	   suggest	   measuring	   HVPG	   in	   patients	   with	  oesophageal	   varices,	  where	   a	   therapeutic	  decision	   should	  be	   taken,	   or,	   after	   acute	  bleeding	  episode,	   to	   assess	   risk	   of	   recurrence4.	   Nonetheless,	   a	   bleeding	   risk	   close	   to	   zero	   has	   been	  proven	   when	   HVPG	   drop	   under	   12	   mmHg	   level	   after	   non-­‐selective	   beta-­‐blockers	   intake41.	  However,	   HVPG	  measurement	   is	   an	   invasive	   technique.	   It	   could	   be	   dangerous	   in	   cirrhotic	  patients	   with	   variable	   degrees	   of	   coagulopathy	   and	   is	   not	   readily	   available	   in	   all	   centres.	  Nonetheless,	  it	  seems	  cost	  effective	  only	  in	  patients	  at	  high	  risk	  of	  variceal	  bleeding	  or	  at	  least	  in	  patient	  with	  a	  3-­‐5	  years	  life	  expectancies42,	  a	  feature	  that	  could	  weight	  on	  clinical	  decision	  in	  a	   setting	  of	   low	   financial	   resources.	  Therefore,	   the	   technique	   is	  not	   suitable	   to	   screen	  all	  cirrhotic	  patients	  suspected	  for	  portal	  hypertension.	  	  New	   promising	   tools	   appeared	   recently	   on	   scene.	   Basing	   on	   ultrasound	   technology,	  they	   are	   safe,	   manageable	   and	   cheap.	   They	   were	   originally	   purposed	   to	   measure	   liver	  stiffness,	   a	   surrogate	   marker	   of	   liver	   fibrosis.	   Transient	   Elastography	   (Fibroscan),	   an	  Echosens	   project,	   has	   been	   the	   first	   elastometric	   machine	   in	   commerce.	   Using	   ultrasound	  wave,	  Fibroscan	  measures	  the	  velocity	  of	  a	  short	  burst	  vibration,	   inside	  a	  4x1	  cm	  ROI	  at	  2,5	  cm	  depth	  from	  skin	  surface.	  Velocity	  of	  mechanical	  vibration	  is	  directly	  related	  to	  stiffness,	  a	  viscoelasticity	   proprieties	   of	   tissue18.	   Large	   casuistic	   validated	   in	   a	   meta-­‐analysis	   study,	  showed	   a	   high	   accuracy	   in	   predicting	   fibrosis	   F419.	   Technical	   features	   of	   Fibroscan	   hardly	  permit	  to	  assess	  stiffness	  in	  other	  organ	  than	  liver.	  Thus,	  the	  technique	  has	  been	  validated	  for	  
liver	  stiffness	  measurement,	  and	  its	  employment	  in	  measuring	  other	  kind	  of	  tissue,	  i.e.	  spleen	  tissue,	  is	  practically	  tangled	  and	  still	  a	  matter	  of	  scientific	  debate43.	  Virtual	  Touch™	  (Siemens	  Medical	   Solution,	   Mountain	   View,	   CA,	   USA)	   has	   been	   recently	   purposed	   by	   Siemens.	   The	  elastometric	   system	   is	   embedded	   on	   a	   common	   US	   device.	   The	   B-­‐mode	   image	   allows	   the	  operator	   to	   explore	   abdomen,	   choosing	   organ,	   areas	   and	  depth	   of	   stiffness	  measurement28.	  Despite	  a	  little	  lower	  accuracy	  than	  Fibroscan	  in	  predicting	  significant	  fibrosis	  and	  cirrhosis,	  Virtual	  Touch™	  is	  more	  handy	  and	  less	  subject	  to	  sampling	  failure29.	  Appearance	   of	   elastometric	   tools	   opened	   new	   interesting	   fields	   of	   research	   and	  stiffness	  as	  been	  purpose	  as	  surrogate	  marker	  of	  portal	  hypertension.	  We	  employed	  Virtual	  Touch™	   to	   measure	   liver	   and	   spleen	   stiffness	   in	   a	   cohort	   of	   40	   consecutive	   patients	   with	  cirrhosis,	  which	  were	  sent	  to	  Radiology	  Unit	  of	  Dr.	  Rita	  Golfieri	  for	  HVPG	  measurement.	  Since	  no	  standard	  quality	  of	  liver	  and	  spleen	  stiffness	  measurements	  has	  been	  validated	  for	  Virtual	  Touch™,	  we	  assessed	  stiffness	  (median	  of	  10	  valid	  measurements	  with	  a	  SR	  of	  60%)	  in	  three	  areas	  of	   liver	  (Right	  Lobe	  Surface,	  Right	  Lobe	  Centre	  and	  Left	  Lobe)	  and	  in	  two	  areas	  of	  the	  spleen	   (Upper	  and	  Lower	  Spleen).	  Mean	  spleen	  stiffness	  value	  was	  3,17±0,55	  m/s	   in	  upper	  spleen	  and	  3,36±0,51	  m/s	  in	  lower	  spleen.	  Liver	  stiffness	  was	  lower	  (2,61±0,76	  m/s	  in	  Right	  Lobe	   Surface,	   2,5±0,62	   m/s	   in	   Right	   Lobe	   Centre	   and	   2,55±0,66	   m/s	   in	   Left	   Lobe),	   in	  accordance	  to	  previous	  papers	  conducted	  with	  either	  Fibroscan43	  or	  Virtual	  Touch™32.	  Global	  success	  rate	  of	  the	  technique	  (Table	  3)	  was	  95,8%	  on	  liver	  (range	  95-­‐97,5%)	  and	  96,3%	  on	  spleen	  (range	  92,5-­‐100%),	  paralleling	  previous	  results	  that	  reported	  a	  97,1%	  SR	  on	  liver	  (in	  a	  recent	  meta-­‐analysis)29	  and	  a	  95,1%-­‐100%	  on	  spleen32,	  44.	   In	  2	  patients	  with	  mild-­‐abundant	  ascites,	   no	   valid	   measurements	   were	   reached	   on	   Right	   Liver	   Surface,	   maybe	   because	   the	  presence	  of	  fluid	  magnified	  the	  movement	  of	  liver	  affecting	  the	  examination.	  In	  a	  patient	  with	  moderate	  steatosis	  and	  29	  BMI,	  an	  invalid	  SR	  (44%)	  was	  achieved	  on	  Right	  Lobe	  Centre.	  The	  presence	  of	   gas	   in	  epigastrium	  avoided	   stiffness	  measurements	  on	  Left	  Lobe	   in	  one	  patient	  
and	  only	   a	  25%	  SR	  was	   achieved	   in	   another	   one,	  maybe	  due	   to	   intense	   cardiac	  movement.	  Three	  patients	   achieved	   a	  non-­‐valid	   SR	   (44%	   in	   all	   three	  patients)	   on	  Upper	   Spleen.	  When	  spleen	   has	   normal	   dimension,	   the	   presence	   of	   diaphragm	   could	   hide	   its	   higher	   portion,	  making	   difficult	   to	   get	   a	   sufficient	   number	   of	   samples.	   Anyway,	   our	   data	   confirm	   a	   better	  performance	  of	  Virtual	  Touch™	  in	  comparison	  to	  Transient	  Elastography,	  which	  was	  reported	  in	   literature	   to	  have	  a	   global	   success	   rate	  of	  85,6%	  on	   spleen43	   and	  79%	  on	   liver,	   in	   a	  vast	  casuistic	  on	  about	  13000	  patients	  over	  5	  years	  experience27.	  	  Preliminary	   studies	   showed	   a	   liver	   stiffness	   correlation	  with	   portal	   hypertension	   at	  HVPG	   level	   lower	   than	   10-­‐12	   mmHg22.	   Some	   cut-­‐offs	   showed	   a	   good	   accuracy	   in	   CSPH	  prediction,	   but	   they	   are	   not	   still	   validated	   22-­‐24.	   In	   our	   study,	   Spearman	   bivariate	   analysis	  showed	   a	   non-­‐significant	   correlation	   between	  HVPG	   and	   liver	   stiffness	   (Right	   Lobe	   Surface	  p=0,176,	  Right	  Lobe	  Centre	  p=0,224	  and	  Left	  Lobe	  p=0,075).	  This	  is	  not	  surprising,	  since	  liver	  stiffness	  is	  the	  outcome	  of	  multiple	  factors	  as	  fibrosis	  deposition,	  inflammatory	  activity45,	  fat	  cell	   deposition	   and	   blood	   flow	   congestion.	   Secondly,	   fibrosis	   deposition	   has	   been	  demonstrated	   to	   be	   extremely	   inhomogeneous46.	   Original	   studies,	   using	   Virtual	   Touch31	   or	  most	  panoramic	  technique	  like	  MRI47,	  showed	  how	  the	  variability	  of	  liver	  stiffness	  increase	  in	  patients	   with	   chronic	   hepatitis	   than	   in	   healthy	   subject	   and	   even	  more	   in	   cirrhosis	   than	   in	  milder	  degree	  of	  fibrosis.	  Seemly	  in	  our	  data,	  IQR	  increases	  together	  to	  the	  elevation	  of	  liver	  stiffness	  (Figure	  1),	  confirming	  an	  extreme	  variability	  of	  sampling	  in	  patients	  with	  a	  severe	  disease	   and	  probably	   affecting	   the	   correlation	  with	  portal	   pressure.	  The	  data	   confirms	  also	  the	   clinical	   evolution	   of	   portal	   hypertension	   that	   is	   usually	   asynchronous	   with	   cirrhosis	  occurrence	   and	   with	   complication	   development1.	   Otherwise,	   spleen	   stiffness	   distribution	  seems	  much	  more	   limited	   to	   a	   single	   area	   in	   the	   scatter	   plot	   of	  Figure	   1.	   Differently	   from	  liver,	  spleen	   is	  not	  affected	  by	   inflammatory	  reaction	  and	  fibrosis	  deposition	  during	  chronic	  hepatitis.	   Intrasplenic	   microvascular	   pressure	   modification	   and	   fluid	   extravasation	   answer	  
directly	  to	  a	  hemodynamic	  reaction	  and	  neuronal	  reflex	  to	  portal	  pressure	  elevation,	  leading	  to	   spleen	   congestion48.	   Consequently,	   during	   portal	   hypertension	   spleen	   stiffness	   should	  increase	  only	  due	   to	   spleen	   congestion,	   as	  well	   as	   liver	   stiffness	   increase	  during	   congestive	  heart	   failure49.	   Indeed,	   a	   good	   correlation	   was	   found	   between	   spleen	   stiffness	   and	   HVPG	  (Upper	   Spleen	   r=0,532,	   p=0,001	   and	   Lower	   Spleen	   r=0,531,	   p<0,001)	   in	   our	   population.	  Moreover,	  when	  we	  computed	  the	  median	  value	  of	  the	  20	  stiffness	  samplings	  in	  both	  superior	  and	  inferior	  spleen,	  correlation	  increases	  to	  0,744	  (p<0,001)	  with	  a	  linear	  distribution	  of	  the	  results	   (Figure	   4).	   The	   data	   confirm	   a	   previous	   Japanese	   report	   where	   portal	   pressure,	  measured	   directly	   in	   a	   small	   group	   of	   transplant	   recipients,	   correlates	   well	   with	   spleen	  stiffness,	   but	   not	   with	   liver	   stiffness50.	   In	   order	   to	   assess	   eventual	   confounders	   factors	   of	  spleens	  stiffness,	  a	  regression	  analysis	  was	  also	  provided.	  BMI	  and	  GPT	  level	  was	  found	  to	  be	  unrelated	  to	  spleen	  stiffness.	  Differently	  from	  liver	  stiffness	  assessed	  with	  Fibroscan,	  BMI	  did	  not	   affect	   stiffness	   assessment27	   as	   well	   as	  major	   changes	   in	   GPT	   level51.	   A	   positive	   linear	  correlation	   was	   found	   out	   with	   Child-­‐Pugh	   levels	   and	   spleen	   dimension.	   Since	   portal	  hypertension	   is	   related	   to	   reduction	  of	   liver	   function	   and	   to	   enlargement	   of	   spleen,	  we	   are	  convinced	   that	   this	   relationship	   could	   not	   affect	   spleen	   stiffness	   measurement	   but	   only	  confirms	   the	   previous	   data,	   corroborating	   the	   good	   performance	   of	   spleen	   stiffness	   in	  assessing	  portal	  hypertension.	  Since	   portal	   pressure	   assessment	   helps	   physician	   to	   stratify	   population	   in	   classes	   of	  growing	  risk,	  we	  tested	  the	  ability	  of	  spleen	  stiffness	  to	  discern	  population	  at	  different	  stage	  of	   PH.	   In	   our	   population,	   patients	  with	   CSPH,	   namely	  HVPG≥10	  mmHg,	   have	   higher	   spleen	  stiffness	   degrees	   (mean	   spleen	   stiffness	   3,5±0,42	   m/s)	   than	   patients	   without	   CSPH	   (mean	  spleen	  stiffness	  2,82±0,32	  m/s)	  as	  displayed	  in	  Figure	  5	  (panel	  A).	  AUROC	  analysis	  confirms	  the	  data,	  showing	  a	  good	  accuracy	  of	  spleen	  stiffness	   in	  predicting	  CSPH.	  The	  best	  cut	  off	  of	  spleen	  stiffness	  was	  3,26	  m/s	  (sens	  69%	  and	  spec	  91%).	  The	  discriminant	  capacity	  of	  spleen	  
stiffness	   will	   drop	   if	   we	   split	   population	   according	   to	   16	   mmHg	   and	   12	   mmHg	   HVPG	  threshold.	  A	  discrete	  area	  of	  overlap	  could	  be	  seen	   in	  between	  HVPG<	  12	  mmHg	  and	  HVPG	  ≥12	  mmHg	  and	  an	  outlier	  with	  high	  stiffness	  value	  (patient	  n°	  30)	   falls	  also	   in	   the	  group	  of	  patients	  with	  HVPG	  <16	  mmHg.	  Thus,	  we	  thought	  that	  ARFI	  does	  not	  allow	  discrimination	  of	  patients	  at	  high	  risk	  of	  decompensating	  or	  death	  related	  to	  PH.	  According	  to	  previous	  data	  of	  our	  group33,	  we	  found	  a	  scarce	  ability	  of	  spleen	  stiffness	  to	  assess	  the	  presence	  of	  varices	  in	  a	  setting	  of	   cirrhotic	  patients.	  The	  presence	  of	  CSPH	  describes	  a	  population	  at	   risk	  of	   varices	  and	  is	  not	  directly	  related	  to	  the	  presence	  of	  them,	  seemly	  the	  surrogate	  marker	  should	  assess	  the	  same	  risk	  and	  not	  predict	  the	  presence	  or	  absence	  of	  varices.	  	  Despite	  good	  results,	  the	  study	  has	  some	  limitations	  and	  it	  should	  be	  considered	  a	  pilot	  study.	  Primarily,	  the	  population	  was	  small	  and	  inhomogeneous,	  with	  the	  presence	  of	  several	  aetiologies	  of	  liver	  disease	  and	  multiple	  degrees	  of	  liver	  dysfunction.	  This	  situation	  reflects	  a	  clinical	  aspect	  of	  our	  Hospital,	  where	  HVPG	  is	  rather	  than	  a	  routinely	  request	  to	  our	  Radiology	  Unit.	  Thus,	  further	  prospective	  study	  should	  verify	  our	  data,	  in	  wider	  cohort	  of	  patients	  with	  single	   chronic	   liver	   disease	   aetiology.	  We	   are	   also	   convinced	   that	   the	   best	   result	  might	   be	  achieved	  by	  monitoring	  both	  liver	  and	  spleen	  stiffness	  in	  cirrhotic	  patients	  in	  order	  to	  verify	  the	  progression	  of	  liver	  disease	  and	  portal	  hypertension,	  correlating	  them	  to	  the	  development	  of	  liver	  related	  complication	  and	  time	  to	  death.	  	  In	   conclusion,	   there	   are	   evidences	   that	  measurements	   of	   spleen	   stiffness	   by	   ARFI	   is	  more	   reliable	   and	   accurate	   in	   predicting	   Clinical	   Significant	   Portal	   Hypertension	   than	   liver	  stiffness,	  and	  that	  should	  be	  taken	  into	  account	  as	  a	  non-­‐invasive	  method	  for	  the	  evaluation	  of	  PH	  in	  patient	  with	  cirrhosis.	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